Work

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.3483.3483

Authors: Irene M. Ghobrial, Raymond Perez, Rachid Baz, Paul G. Richardson, Kenneth C. Anderson, Peter Sabbatini, Clifford Dilea, Pina M. Cardarelli, Mark Wade, Guan Xing, Andres Gutierrez, Lewis Cohen, Pamela S. Becker

Institutions: Harvard University, Dana-Farber Cancer Institute, University of Kansas, Moffitt Cancer Center, Dana-Farber/Harvard Cancer Center, Bristol-Myers Squibb (United States), University of Washington

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4241966903

FWCI: 1.638

Cites:

Cited by: 15

Related to: 10